Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 mrt 2008 - 07:37
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Vaccine Development Agreement with Wyeth Pharmaceuticals
Bericht
Leiden, The Netherlands, 3 March 2008 - Dutch biotechnology company Crucell N.V. today announced that it has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities will take place in Crucell’s dedicated vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed.
Gerelateerde downloads
Datum laatste update: 22 december 2025